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With the expansion of indications for implantable
cardioverter-deﬁbrillators (ICDs) for primary and secondary
prevention of sudden cardiac death, >100,000 implanta-
tions of these devices are performed annually in the United
States (1,2). Of these, w25% are replacements of existing
devices because of battery depletion (1,2). The multiple
clinical trials deﬁning patient groups beneﬁting from ICD
therapy provide a strong evidence base for initial
implantation guidelines developed by professional societies
(1). The evidence is considerably less robust related to
clinical reassessment to ensure that the patient continues to
meet criteria at the time of device replacement (2). Clinical
trials comparing outcomes in patients at the time of ICD
replacement have not been conducted (2). This lack of
empirical data on outcomes after ICD replacement at the
time of battery depletion has prevented the development of
evidence-based recommendations to guide clinicians (2).
In the absence of such guidance, clinicians may feel com-
pelled by ethical or legal considerations to replace the ICD
regardless of whether the patient still meets implantation
criteria (2). Misaligned economic incentives may inﬂuence
replacement decisions as well (2). Although the risks asso-
ciated with ICD replacement have been evaluated, the
beneﬁts and costs remain unknown (3). Whether the com-
mon practice of replacement without ensuring that guide-
line criteria are still met is the appropriate clinical strategy
remains unknown (2).See page 2388Some of the very limited available evidence related to this
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Boston Scientiﬁc, Medtronic, and St. Jude Medical.patients with recovered ejection fractions (4). Outcomes
were evaluated in 91 consecutive patients with ICDs placed
for primary prevention of sudden death who underwent
generator replacement with reassessment of guideline-based
implantation criteria. Most of these patients had ischemic
heart disease (76%) (4). At generator replacement, 25 pa-
tients had an improvement of the left ventricular ejection
fraction (LVEF) of at least 10% and to >35% (4). These
patients had an LVEF of 49% compared with 32% at
baseline (p < 0.0001). During 6.2  2.2 years of follow-up
after the original implantation, 9 patients (36%) with an
improved LVEF compared with 19 patients (29%) with an
unchanged LVEF had appropriate ICD shocks (p ¼ 0.51).
The incidence of appropriate ICD shocks was similar
between the 2 groups before (p ¼ 0.90) and after (p ¼ 0.97)
generator replacement (4). Of the 9 patients with an im-
proved LVEF with appropriate shock, 4 had shocks before
generator replacement, 2 had shocks before and after
generator replacement, and 3 patients, who never had shocks
before, had their ﬁrst shock after generator replacement (4).
On the basis of these observations, the authors conclude that
some ICD patients whose LVEF improves to >35% at
generator replacement remain at risk of appropriate ICD
shocks (4).
Additional data are available in patients with nonische-
mic cardiomyopathy from the DEFINITE (Deﬁbrillators
in Non-Ischemic Cardiomyopathy Treatment Evaluation
Trial), which randomized patients with nonischemic car-
diomyopathy and an LVEF <36% and frequent ventricular
premature contractions or nonsustained ventricular tachy-
cardia to optimal medical therapy alone or with an ICD
(5). ICD implantation caused a signiﬁcant reduction in
arrhythmic sudden death (p < 0.006) associated with a
trend toward a reduction in total mortality (p < 0.08) (5).
An analysis was performed of survival and arrhythmic end-
points in patients whose LVEF was reassessed between 90
and 730 days after enrollment (5). Patients whose LVEF
improved had reduced mortality compared with patients
whose LVEF decreased (hazard ratio: 0.09, p < 0.001) (5).
However, survival free of appropriate shocks was not
signiﬁcantly related to LVEF improvement during follow-
up (5). On the basis of these observations, the authors
concluded that LVEF improvement was associated with
improved survival, but not with a signiﬁcant decrease in
appropriate shocks (5). They also note that these data
highlight that appropriate caution should be exercised to not
extrapolate the positive effect of improved LVEF to the
elimination of arrhythmic events (5).
In this issue of the Journal, additional observations are
reported from an investigation by Kini et al. (6) addressing
the appropriateness of replacing primary prevention ICDs
at time of generator replacement. The investigators per-
formed a retrospective analysis of patients undergoing re-
placement in the Veterans Affairs hospital system (6).
The indications for continued ICD therapy were deﬁned as
an LVEF <35% or receiving appropriate device therapy (6).
Estes JACC Vol. 63, No. 22, 2014
A New Approach to ICD Replacement? June 10, 2014:2395–7
2396Of the 231 patients analyzed, 59 (26%) no longer met
guideline indications for an ICD at the time of generator
replacement (6). An additional 79 patients (34%) had
not received any appropriate ICD therapies and had not
undergone reassessment of their LVEF (6). Patients with an
initial LVEF of 30% to 35% were less likely to meet
indications for ICD therapy at the time of replacement (odds
ratio: 0.52, p ¼ 0.01) (6). Patients without ICD indications
subsequently received appropriate ICD therapies at a
signiﬁcantly lower annual rate than patients who with in-
dications (2.8% vs. 10.7%) (6).
There are many limitations of the study including its
retrospective design, inclusion of only male veterans,
observational rather than interventional nature, and lack of
complete clinical data in a minority of patients (6). The cost
data were modeled, and a robust cost-effectiveness analysis
was not performed (6). They state that their observations
make the case to perform ICD explantations instead of
generator replacement in patients who experience no
appropriate therapies and show signiﬁcant improvement in
the LVEF when their devices reach elective replacement
indications (6). In addition, they conclude that in the pa-
tients in whom improvement of LVEF has occurred with
the original device being cardiac resynchronization therapy
(CRT) with a deﬁbrillator, CRT without a deﬁbrillator
device could be used instead of CRT with a deﬁbrillator for
replacement (6). The authors’ conclusions are bold when
considered in the context of the limitations of the data and
other available evidence. Although this study extends avail-
able evidence, the data presented are insufﬁcient to resolve
the fundamental issue of the appropriateness of ICD
replacement at the time of battery depletion in patients who
no longer meet initial indications for ICD implantation.
Other studies examining the time dependence of ICD
therapy in patients with primary prevention devices provide
appropriate context for consideration of the Kini et al. study
(6,7). The incidence and time dependence of ﬁrst appro-
priate ICD therapy for ventricular arrhythmia and rapid
ventricular tachycardia (cycle length 260 ms) have been
reported in 525 ICD patients with primary prevention ICDs
implanted because of previous MI and LVEF 35% (7).
Overall, 115 (22%) had appropriate ICD therapy (7). The
incidence of ﬁrst appropriate ICD therapy was highest in
the ﬁrst year post-implantation (20%), decreased to 12% in
year 2, and remained at 6% to 11% yearly thereafter for up to
7 years (7). A similar trend was observed with rapid ven-
tricular arrhythmias: a higher risk in the ﬁrst year (6%) and a
lower but persistent risk thereafter (3.8% in year 7) (7). In
this patient group with previous MI and an LVEF 35%,
the incidence of ﬁrst ICD therapy for ventricular arrhyth-
mias is highest in the ﬁrst year post-implantation and per-
sists for up to 7 years thereafter (7). The authors concluded
that risk of ﬁrst appropriate ICD therapy persists over time,
and thus replacement of ICDs appears to be indicated for
all patients (7). However, analysis was not performed on thebasis of reassessment of the initial implantation criteria at
the time of elective battery replacement (7).
The MADIT II analysis has the robust endpoint of total
mortality rather than appropriate ICD therapy use in the
Kini et al. (6) and other studies (8). It has been well
established that using ICD therapy as a surrogate endpoint
results in exaggeration of mortality beneﬁt (9). It has also
become evident that although many therapies for ventricular
arrhythmias are appropriate, they are unnecessary and in-
crease mortality (10). The MADIT-RIT (Multicenter
Automatic Deﬁbrillator Implantation Trial-Reduce In-
appropriate Therapy) study demonstrated that program-
ming of ICD therapies for tachyarrhythmias of 200
beats/min or with a prolonged delay in therapy at 170
beats/min, compared with conventional programming, was
associated with reductions in inappropriate and appropriate
therapy and all-cause mortality during long-term follow-up
(10). Relevant data on time dependence of ICD therapies
and mortality in primary prevention with contemporary
programming analyzed on the basis of reassessment of ejec-
tion fraction after implantation or at the time of replacement
are not available (10).
Kini et al. (6) have brought an important clinical issue to
the forefront. Their data do support the case to perform ICD
explants instead of generator replacement in patients with no
appropriate therapies and signiﬁcant improvement of the
LVEF. However, it is evident that there are many gaps in
current knowledge related to the optimal ICD replacement
strategy. Even with the additional observations of Kini et al.,
these gaps prevent resolution of this important issue using
the standards of evidence-based medicine. Prospective
studies are needed of patients at high or low risk of sudden
death who are eligible for ICD replacement to identify pa-
tient groups that are unlikely to beneﬁt from therapy (2).
In the meantime, it is time for a new approach to elective
replacements of ICDs. If the LVEF improves at the time
of reevaluation such that a patient no longer meets im-
plantation criteria and has not had appropriate therapy, it is
reasonable to have a discussion with the patient regarding
the risk of replacement and uncertain beneﬁt. Patients
should have a life expectancy of at least 1 year with a
reasonable quality of life to justify ICD replacement (1,2).
Finally, careful reassessment of the patient’s desire for life-
sustaining therapies should be undertaken with a informed
discussion of their cardiac and general medical status, quality
of life, and life expectancy. From a societal perspective, this
approach should result in savings (2). Ultimately, in the
setting of uncertainty, a deferential approach to patient pre-
ference is always a prudent approach (11). Electively with-
drawing a potentially life-sustaining therapy such as an ICD
by not replacing it is justiﬁed and appropriate from both
ethical and legal perspectives (11). Although this new
approach is reasonable, it is one based on very limited data.
Deﬁning the optimal approach will require clinical trials and
registries to bridge the many gaps in our current knowledge.
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